首页> 外文期刊>Bone marrow transplantation >Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study.
【24h】

Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study.

机译:移植前合并症对不同疾病状态和移植时间的影响,对移植前合并症的预后影响不同:一项日本移植中心研究。

获取原文
获取原文并翻译 | 示例
       

摘要

This retrospective study examined the differences in the prognostic impact of the haematopoietic cell transplantation-specific comorbidity index (HCT-CI) on transplant outcomes by disease status and time from transplant in allogeneic haematopoietic stem cell transplantation (HSCT) recipients at a Japanese transplant centre. Of 187 patients, nonrelapse mortality (NRM) at 3 years was 9.6, 21.2 and 27.8% in the low-risk (score 0), intermediate-risk (score 1-2) and high-risk (score > or =3) HCT-CI groups, respectively (P=0.03). The corresponding overall survival (OS) at 3 years was 70.1, 60.5 and 38.9%, respectively (P<0.01). In multivariate analyses, high-risk HCT-CI significantly predicted higher NRM (relative risk, (RR) 2.44 (95% confidence interval, (CI) 1.02-5.85); P=0.04) and worse OS (RR 2.02 (95% CI 1.15-3.54); P=0.01). In the subgroup analysis according to disease status, the HCT-CI was associated with OS (P<0.01) and NRM (P=0.07) in patients with low-risk diseases, but not in those with high-risk diseases. Within patients who survived without relapse >1 year after HSCT, the HCT-CI did not predict OS (P=0.59) or NRM (P=0.31). These findings can be useful to determine the role of pretransplant comorbidity in allogeneic HSCT.
机译:这项回顾性研究研究了异基因造血干细胞移植(HSCT)受者在日本移植中心的造血细胞移植特异性合并症指数(HCT-CI)对疾病结果和移植时间对预后的影响。在187例患者中,低危(评分0),中危(评分1-2)和高危(评分>或= 3)HCT在3年时的非复发死亡率(NRM)分别为9.6、21.2和27.8%。 -CI组分别(P = 0.03)。 3年相应的总生存(OS)分别为70.1%,60.5%和38.9%(P <0.01)。在多变量分析中,高风险HCT-CI显着预测了较高的NRM(相对风险(RR)2.44(95%置信区间,(CI)1.02-5.85); P = 0.04)和较差的OS(RR 2.02(95%CI) 1.15-3.54); P = 0.01)。在根据疾病状况进行的亚组分析中,HCT-CI与低风险疾病患者的OS(P <0.01)和NRM(P = 0.07)相关,而与高风险疾病患者无关。在HSCT后未复发> 1年而未复发的患者中,HCT-CI不能预测OS(P = 0.59)或NRM(P = 0.31)。这些发现对于确定移植前合并症在异基因HSCT中的作用可能是有用的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号